Celldex Therapeutics reported $64.59M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Celldex Therapeutics USD 64.59M 1.15M Jun/2025
Glaxosmithkline GBP 5.55B 1.87B Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024